Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M. by Lisa Stiffler on January 7, 2025 at 10:07 am January 7, 2025 at 10:10 am. Share 7 Tweet Share Reddit Email.

Variant Bio has entered a multi-year research partnership with Novo Nordisk, focusing on the identification of new targets to treat metabolic conditions. Leveraging Variant’s ‘VB-Inference ...

"Having conducted over two dozen genomic research projects with diverse populations around the world, Variant Bio is well positioned to carry out genomic research on metabolic disease in places ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes. By Brendan Borrell When Stephane Castel first ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.

Collaboration leverages Variant Bio's innovative VB-Inference Platform and expertise partnering with global populations Commercial terms include an upfront payment and additional near-term R&D ...

Genetic material is deeply personal, and powerful. Now, Seattle-based Variant Bio has a plan to develop drugs for metabolic disorders, using data collected from Indigenous populations. In exchange ...